mephenytoin has been researched along with Depressive Disorder in 9 studies
Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.
mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.
Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No evidence was seen of a pharmacokinetic interaction between CIT and Li, and this combination was well tolerated." | 2.68 | A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. ( Amey, M; Baettig, D; Baumann, P; Jonzier-Perey, M; Kasas, A; Lambert, S; Montaldi, S; Nil, R; Souche, A; Uehlinger, C, 1996) |
| " In many instances, a knowledge of the drug metabolism status of a patient can be helpful in the selection of a drug and its dosage regimen, and in the prediction of possible drug/drug interactions when two or more drugs have to be administered concomitantly." | 2.39 | Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. ( Coutts, RT, 1994) |
| "The debrisoquine-test appears to be a useful clinical tool for detecting in patients a genetic deficiency in the hydroxylation of AT-type drugs." | 1.27 | Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. ( Baumann, P; Jonzier-Perey, M; Koeb, L; Küpfer, A; Schöpf, J; Tinguely, D, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coutts, RT | 1 |
| Seifritz, E | 1 |
| Holsboer-Trachsler, E | 1 |
| Hemmeter, U | 1 |
| Eap, CB | 2 |
| Baumann, P | 6 |
| Guentert, TW | 1 |
| Schãublin-Loidl, M | 1 |
| Stabl, M | 1 |
| Koeb, L | 3 |
| Powell, K | 1 |
| Koyama, E | 1 |
| Tanaka, T | 1 |
| Chiba, K | 1 |
| Kawakatsu, S | 1 |
| Morinobu, S | 1 |
| Totsuka, S | 1 |
| Ishizaki, T | 1 |
| Nil, R | 1 |
| Souche, A | 1 |
| Montaldi, S | 1 |
| Baettig, D | 1 |
| Lambert, S | 1 |
| Uehlinger, C | 1 |
| Kasas, A | 1 |
| Amey, M | 1 |
| Jonzier-Perey, M | 2 |
| Meyer, JW | 1 |
| Woggon, B | 2 |
| Küpfer, A | 2 |
| Bosshart, P | 1 |
| Gabris, G | 1 |
| Gastpar, M | 1 |
| Tinguely, D | 1 |
| Schöpf, J | 1 |
1 review available for mephenytoin and Depressive Disorder
| Article | Year |
|---|---|
Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.
Topics: Clomipramine; Cytochromes; Dealkylation; Depressive Disorder; Desipramine; Dextromethorphan; Drug In | 1994 |
2 trials available for mephenytoin and Depressive Disorder
| Article | Year |
|---|---|
Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.
Topics: Adult; Aged; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Antitussive Agents; Aryl | 1996 |
A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation.
Topics: Adult; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Citalopram; Cytochrome P-450 CYP2C19; C | 1996 |
6 other studies available for mephenytoin and Depressive Disorder
| Article | Year |
|---|---|
Increased trimipramine plasma levels during fluvoxamine comedication.
Topics: Aged; Citalopram; Depressive Disorder; Dextromethorphan; Drug Interactions; Female; Fluvoxamine; Hum | 1994 |
Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
Topics: Adult; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cy | 1996 |
Importance of oxidative polymorphism on clinical efficacy and side-effects of imipramine--a retrospective study.
Topics: Debrisoquin; Depressive Disorder; Female; Humans; Imipramine; Male; Mephenytoin; Middle Aged; Oxidat | 1988 |
Acetylation of maprotiline and desmethylmaprotiline in depressive patients phenotyped with sulfamidine, debrisoquine, and mephenytoin.
Topics: Acetylation; Anthracenes; Debrisoquin; Depressive Disorder; Gas Chromatography-Mass Spectrometry; Hu | 1988 |
Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.
Topics: Adult; Amitriptyline; Debrisoquin; Depressive Disorder; Female; Humans; Hydantoins; Hydroxylation; I | 1986 |
New aspects in research on blood levels and bioavailability of antidepressants.
Topics: Amitriptyline; Antidepressive Agents; Biological Availability; Debrisoquin; Depressive Disorder; Hum | 1986 |